Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life

References

• Böckelman C, Engelmann BE, Kaprio T, et al. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 2015;54:5–16.
   PubMed Web of Science ®Google Scholar
• Påhlman L, Hohenberger W, Sugihara K, et al. Should the benefit of adjuvant chemotherapy in colon cancer be re-evaluated? J Clin Oncol 2016;34:1297–9.
   PubMed Web of Science ®Google Scholar
• Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 2015;14:1–10.
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Moundedji-Boudiaf L, et al. Oxaliplatin, Fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Eng J Med 2004;350:2343–51.
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, ÓConnel MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198–204.
   PubMed Web of Science ®Google Scholar
• Haller D, Tabernero J, Maroun JA, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465–71.
   PubMed Web of Science ®Google Scholar
• Sereno M, Gutiérrez-Gutiérrez G, Gómez-Raposo C, et al. Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol 2014;89:166–78.
   PubMed Web of Science ®Google Scholar
• Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 2015;54:587–91.
   PubMed Web of Science ®Google Scholar
• Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leukovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25:2205–11.
   PubMed Web of Science ®Google Scholar
• Beijers AJM, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 2014;22:1999–2007.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013;31:2699–707.
   PubMed Web of Science ®Google Scholar
• Storey DJ, Sakala M, McLean CM, et al. Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy. Ann Oncol 2010;21:1657–61.
   PubMed Web of Science ®Google Scholar
• Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National surgical adjuvant breast and bowel project trials C-07 and LTS-01. Cancer 2012;118:5614–22.
   PubMed Web of Science ®Google Scholar
• Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41:1135–9.
   PubMed Web of Science ®Google Scholar
• Lavoie Smith EM, Barton DL, Qin R, et al. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European organization for research and treatment of cancer QLQ-CIPN20 questionnaire. Qual Life Res 2013;22:2787–99.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Ca Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
   PubMedGoogle Scholar
• Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 scoring manual. 3rd ed. European Organisation for Research and Treatment of Cancer: Brussels, 2001.
   Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care 2003;41:582–92.
   PubMed Web of Science ®Google Scholar
• Singer MA, Vernino SA, Wolfe GI. Idiopathic neuropathy: new paradigms, new promise. J Peripher Nerv Syst 2012;17S:43–9.
   Web of Science ®Google Scholar
• Andre T, De Gramont A, Vernerey D, et al. Adjuvant fluorouracil leucovorin and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015;33:4176–87.
   PubMed Web of Science ®Google Scholar
• Beijers AJM, Mols F, Tjan-Heijnen VCG, et al. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol 2015;54:463–9.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012;23:3116–22.
   PubMed Web of Science ®Google Scholar
• Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 2015;33:3416–22.
   PubMed Web of Science ®Google Scholar
• Altaf R, Brixen Lund A, Kristensen B, et al. Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. Oncology 2014;87:167–72.
   PubMed Web of Science ®Google Scholar
• Alberti P, Rossi E, Cornblath DR, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 2014;25:257–64.
   PubMed Web of Science ®Google Scholar
• Derogar M, Van der Schaaf M, Lagergren P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol 2012;51:10–16.
   PubMed Web of Science ®Google Scholar